Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA1211 in chronic hepatitis B
NCT07275918Phase 1Recruiting
- Sponsor
- Suzhou Siran Biotech
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SA1211 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Suzhou Siran Biotech. Primary endpoints: Adverse Events at 24 weeks, Serious Adverse Events at 24 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
SA1211
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07275918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275918.